Neurodegeneration risk factor, EIF2AK3 (PERK), influences tau protein aggregation
Journal of Biological Chemistry · 2023-02 · 299 (2) · 102821
DOI: 10.1016/j.jbc.2022.102821 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023-02. Verfasst von Goonho Park und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University, Palo Alto, California, USA; VA Palo Alto Healthcare System, Palo Alto, California, USA. Hauptthemen laut MEDLINE: eIF-2 Kinase, Protein Aggregates, Protein Aggregation, Pathological, tau Proteins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, RRD VA, NINDS NIH HHS.
Abstract (Originalsprache)
Tauopathies are neurodegenerative diseases caused by pathologic misfolded tau protein aggregation in the nervous system. Population studies implicate EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3), better known as PERK (protein kinase R-like endoplasmic reticulum kinase), as a genetic risk factor in several tauopathies. PERK is a key regulator of intracellular proteostatic mechanisms-unfolded protein response and integrated stress response. Previous studies found that tauopathy-associated PERK variants encoded functional hypomorphs with reduced signaling in vitro. But, it remained unclear how altered PERK activity led to tauopathy. Here, we chemically or genetically modulated PERK signaling in cell culture models of tau aggregation and found that PERK pathway activation prevented tau aggregation, whereas inhibition exacerbated tau aggregation. In primary tauopathy patient brain tissues, we found that reduced PERK signaling correlated with increased tau neuropathology. We found that tauopathy-associated PERK variants targeted the endoplasmic reticulum luminal domain; and two of these variants damaged hydrogen bond formation. Our studies support that PERK activity protects against tau aggregation and pathology. This may explain why people carrying hypomorphic PERK variants have increased risk for developing tauopathies. Finally, our studies identify small-molecule augmentation of PERK signaling as an attractive therapeutic strategy to treat tauopathies by preventing tau pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University, Palo Alto, California, USA; VA Palo Alto Healthcare System, Palo Alto, California, USA.
- Department of Pathology, Stanford University, Palo Alto, California, USA.
- VA Palo Alto Healthcare System, Palo Alto, California, USA.
- Department of Pathology, Stanford University, Palo Alto, California, USA; VA Palo Alto Healthcare System, Palo Alto, California, USA; Department of Pharmaceutical Engineering, Soonchunhyang University, Asan, Republic of…
- Department of Pharmacology, UC San Diego, La Jolla, California, USA.
- Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Cheonan, Republic of Korea.
Förderung
- BLRD VA
- RRD VA
- NINDS NIH HHS
- American Federation for Aging Research
- NIH
- Soonchunhyang University
- Department of Veterans Affairs
Zitieren
APA
Park, G., Xu, K., Chea, L., Kim, K., Safarta, L., Song, K. H., Wu, J., Park, S., Min, H., Hiramatsu, N., Han, J., & Lin, J. H. (2023). Neurodegeneration risk factor, EIF2AK3 (PERK), influences tau protein aggregation. Journal of Biological Chemistry, 299(2), 102821. https://doi.org/10.1016/j.jbc.2022.102821
Vancouver
Park G, Xu K, Chea L, Kim K, Safarta L, Song KH, et al. Neurodegeneration risk factor, EIF2AK3 (PERK), influences tau protein aggregation. Journal of Biological Chemistry. 2023;299(2):102821. doi:10.1016/j.jbc.2022.102821
BibTeX
@article{Park2023,
author = {Park, Goonho and Xu, Ke and Chea, Leon and Kim, Kyle and Safarta, Lance and Song, Keon-Hyoung and Wu, Jian and Park, Soyoung and Min, Hyejung and Hiramatsu, Nobuhiko and Han, Jaeseok and Lin, Jonathan H},
title = {Neurodegeneration risk factor, EIF2AK3 (PERK), influences tau protein aggregation},
journal = {Journal of Biological Chemistry},
year = {2023},
volume = {299},
number = {2},
pages = {102821},
doi = {10.1016/j.jbc.2022.102821}
}
EUVIMED